Duong, T. A., Valeyrie-Allanore, L., Wolkenstein, P. & Chosidow, O. Severe cutaneous adverse reactions to drugs. Lancet 390, 1996–2011 (2017).

Article  CAS  PubMed  Google Scholar 

Bellón, T. Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf. 42, 973–992 (2019).

Article  PubMed  Google Scholar 

Gibson, A. et al. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. J. Allergy Clin. Immunol. 151, 289–300.e4 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roujeau, J. C. & Stern, R. S. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331, 1272–1285 (1994).

Article  CAS  PubMed  Google Scholar 

Chu, M.-T., Chang, W.-C., Pao, S.-C. & Hung, S.-I. Delayed drug hypersensitivity reactions: molecular recognition, genetic susceptibility, and immune mediators. Biomedicines 11, 177 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Bastuji-Garin, S. et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129, 92–96 (1993).

Article  CAS  PubMed  Google Scholar 

Mockenhaupt, M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev. Clin. Immunol. 7, 803–813 (2011).

Article  PubMed  Google Scholar 

Roujeau, J. C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J. Invest. Dermatol. 102, 28S–30S (1994).

Article  CAS  PubMed  Google Scholar 

Howland, W. W., Golitz, L. E., Weston, W. L. & Huff, J. C. Erythema multiforme: clinical, histopathologic, and immunologic study. J. Am. Acad. Dermatol. 10, 438–446 (1984).

Article  CAS  PubMed  Google Scholar 

Roujeau, J. C. et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333, 1600–1607 (1995). To our knowledge, the first case–control study of the risk of SJS/TEN following drug use.

Article  CAS  PubMed  Google Scholar 

Mockenhaupt, M. et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol. 128, 35–44 (2008).

Article  CAS  PubMed  Google Scholar 

Pichler, W. J. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139, 683–693 (2003).

Article  CAS  PubMed  Google Scholar 

Chung, W. H. et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 14, 1343–1350 (2008). Study reporting that granulysin triggers keratinocyte death in SJS/TEN.

Article  CAS  PubMed  Google Scholar 

Pan, R. Y., Chu, M. T., Wang, C. W., Lee, Y. S. & Lemonnier, F. Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nat. Commun. 10, 3569 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Pichler, W. J. Immune pathomechanism and classification of drug hypersensitivity. Allergy 74, 1457–1471 (2019).

Article  CAS  PubMed  Google Scholar 

Villani, A. P. et al. Massive clonal expansion of polycytotoxic skin and blood CD8+ T cells in patients with toxic epidermal necrolysis. Sci. Adv. 7, eabe001 (2021).

Article  Google Scholar 

Jutel, M. et al. Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper. Allergy 78, 2851–2874 (2023).

Article  CAS  PubMed  Google Scholar 

Chung, W. H. et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004). Study reporting the association between HLA-B*15:02 and carbamazepine SJS/TEN.

Article  CAS  PubMed  Google Scholar 

Hung, S. I. et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102, 4134–4139 (2005). Study reporting the association between HLA-B*58:01 and risk of allopurinol SCARs.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lonjou, C. et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18, 99–107 (2008).

Article  CAS  PubMed  Google Scholar 

Chung, W. H. et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 312, 525–534 (2014). Article discussing impaired drug metabolism and SCARs.

Article  PubMed  Google Scholar 

Su, S. C. et al. HLA alleles and CYP2C9*3 as predictors of phenytoin hypersensitivity in East Asians. Clin. Pharmacol. Ther. 105, 476–485 (2019).

Article  CAS  PubMed  Google Scholar 

Viard, I. et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490–493 (1998). Study reporting that FASL-mediated cell apoptosis could be inhibited by IVIg therapy for SJS/TEN.

Article  CAS  PubMed  Google Scholar 

Nassif, A. et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114, 1209–1215 (2004).

Article  CAS  PubMed  Google Scholar 

Picard, D. et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci. Transl. Med. 2, 46ra62 (2010).

Article  PubMed  Google Scholar 

Cacoub, P. et al. The DRESS syndrome: a literature review. Am. J. Med. 124, 588–597 (2011).

Article  CAS  PubMed  Google Scholar 

Kardaun, S. H. et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br. J. Dermatol. 169, 1071–1080 (2013).

Article  CAS  PubMed  Google Scholar 

Wei, B. M. et al. Drug-induced hypersensitivity syndrome / drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. J. Am. Acad. Dermatol. https://doi.org/10.1016/j.jaad.2023.02.072 (2023).

Article  PubMed  Google Scholar 

Shiohara, T. & Mizukawa, Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol. Int. 68, 301–308 (2019).

Article  CAS  PubMed  Google Scholar 

Bluestein, S. B., Yu, R., Stone, C. Jr. & Phillips, E. J. Reporting of drug reaction with eosinophilia and systemic symptoms from 2002 to 2019 in the US Food and Drug Administration Adverse Event Reporting System. J. Allergy Clin. Immunol. Pract. 9, 3208–3211.e1 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hetherington, S. et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121–1122 (2002).

Article  CAS  PubMed  Google Scholar 

Mallal, S. et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727–732 (2002). Study reporting an association between HLA-B*57:01 and abacavir hypersensitivity.

Article  CAS  PubMed  Google Scholar 

Hung, S. I. et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16, 297–306 (2006).

Article  CAS  PubMed  Google Scholar 

McCormack, M. et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134–1143 (2011). Study reporting an association between HLA-A*31:01 and carbamazepine hypersensitivity.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Genin, E. et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J. 14, 281–288 (2014).

Article  CAS  PubMed  Google Scholar 

Zhang, F. R. et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N. Engl. J. Med. 369, 1620–1628 (2013). Study reporting an associaton between HLA-B*13:01 and dapsone hypersensitivity syndrome.

Article  CAS  PubMed  Google Scholar 

Konvinse, K. C. et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J. Allergy Clin. Immunol. 144, 183–192 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roujeau, J. C. et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch. Dermatol. 127, 1333–1338 (1991).